This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Dapagliflozin - no longer authorised for treatment of type 1 diabetes mellitus in Europe and the UK

Authoring team

In Europe and the UK authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged (1)

Advice for healthcare professionals:

  • dapagliflozin 5 mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus
  • the removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged
  • dapagliflozin should be reviewed and discontinued in patients with type 1 diabetes by or in consultation with a physician specialised in diabetes care as soon as clinically practical
  • after stopping dapagliflozin treatment, frequent blood glucose monitoring is recommended
  • an increased insulin dose may be needed, which should be undertaken carefully to minimise the risk of hypoglycaemia or hyperglycaemia
  • diabetic ketoacidosis is a known risk with use of dapagliflozin in all patients with diabetes, but it occurs more frequently in patients with type 1 diabetes than those with type 2 diabetes
  • additional risk minimisation materials to mitigate the risks in patients with type 1 diabetes are no longer available
  • report suspected adverse drug reactions associated with use of dapagliflozin on a Yellow Card

Advice for healthcare professionals to give to patients and carers:

  • always seek advice from your doctor or diabetes team before making changes to your diabetes medicines
  • the manufacturer of dapagliflozin (Forxiga) has voluntarily withdrawn its use in type 1 diabetes
  • this decision was not linked to a new safety issue and other patients using dapagliflozin for type 2 diabetes, heart failure, or chronic kidney disease can continue taking their medicine as recommended by a healthcare professional
  • if you take dapagliflozin for your type 1 diabetes, your specialist will help you safely discontinue this treatment – you will need to monitor your blood glucose levels more closely to prevent hypoglycaemia or hyperglycaemia in the transition

Reference

  • Drug Safety Update volume 15, issue 5: December 2021: 3.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.